Renal trials in diabetes need a platform: time for a global approach?

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 5, 2018, Pages 356-358

  de Zeeuw, Dick ^a   Heerspink, Hiddo J L ^a   Jardine, Meg ^b,c   Perkovic, Vlado ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CANAGLIFLOZIN; FINERENONE;

ALBUMINURIA; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY DISEASE; MORTALITY RATE; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT RESPONSE; DIABETIC NEPHROPATHY; KIDNEY; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY;

EID: 85027191186     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30263-2     Document Type: Note

References (8)

1. Tuomi, T, Santoro, N, Caprio, S, Cai, M, Weng, J, Groop, L, The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383 (2014), 1084–1094.
2. Oxlund, CS, Henriksen, JE, Tarnow, L, Schousboe, K, Gram, J, Jacobsen, IA, Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 31 (2013), 2094–2102.
3. de Zeeuw, D, Coll, B, Andress, D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25 (2014), 1083–1093.
4. Petrykiv, SI, Laverman, GD, Zeeuw, D, Heerspink, HJL, The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes Metab, 2017 published online March 14. DOI:10.1111/dom.12936.
5. de Zeeuw, D, Heerspink, HJ, Unmet need in diabetic nephropathy: failed drugs or trials?. Lancet Diabetes Endocrinol 4 (2016), 638–640.
6. Saville, BR, Berry, SM, Efficiencies of platform clinical trials: a vision of the future. Clin Trials 13 (2016), 358–366.
7. Berry, SM, Connor, JT, Lewis, RJ, The platform trial: an efficient strategy for evaluating multiple treatments. JAMA 313 (2015), 1619–1620.
8. Heerspink, HJL, Grobbee, DE, de Zeeuw, D, A novel approach for establishing cardiovascular drug efficacy. Nat Rev Drug Discov, 13, 2014, 942.